<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229993</url>
  </required_header>
  <id_info>
    <org_study_id>OCT-20170723</org_study_id>
    <nct_id>NCT03229993</nct_id>
  </id_info>
  <brief_title>OCT in Borderline Coronary Artery Lesions</brief_title>
  <official_title>The Safety and Efficacy of OCT in the Evaluation and Treatment of Angiographically Borderline Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out the safety and efficacy of Optical Coherence Tomography (OCT) in the evaluation
      and treatment of angiographically borderline coronary artery lesions in a Chinese population,
      and to compare the effectiveness of OCT versus SPECT in treating such subjects. All the
      participants included in the study will be those that are found to have borderline coronary
      artery lesions on coronary angiography, in whom the investigators feel that OCT will be
      useful to assess whether PCI will be of benefit to the treatment of the lesion pathology, or
      whether optimal medical therapy is the most appropriate treatment modality. Those
      participants who declined OCT will be offered SPECT as an alternative method to assess and
      treat the borderline coronary artery stenosis.

      It is estimated that OCT guided &quot;PCI or not&quot; has a non-inferiority to SPECT's in the
      borderline coronary artery stenosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACEs</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of major adverse cardiac events (MACEs) including death, myocardial infarction, and stent thrombosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TLR</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of rehospitalization due to cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent angina</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of recurrent angina</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Optical Coherence Tomography (OCT)</condition>
  <condition>Percutaneous Coronary Intervention (PCI)</condition>
  <condition>Single-Photon Emission Computed Tomography (SPECT)</condition>
  <condition>Coronary Angiography (CAG)</condition>
  <condition>Borderline Coronary Artery Lesions</condition>
  <arm_group>
    <arm_group_label>OCT guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OCT guided medicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPECT guided PCI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPECT guided medicine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions</description>
    <arm_group_label>OCT guided PCI</arm_group_label>
    <arm_group_label>OCT guided medicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria for this study will be only those participants in whom
             diagnostic coronary angiography revealed borderline coronary artery lesion. These
             participants will undergo the OCT procedure, or alternatively ECT.

        Exclusion Criteria:

          -  Exclusion criteria will be those participants with previous cardiogenic shock, stroke,
             renal dysfunction, and acute or chronic total occlusion coronary lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liansheng Wang, Doctor</last_name>
    <phone>86 25 68303125</phone>
    <email>drlswang@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haoyu Meng, Doctor</last_name>
    <phone>86 25 68303126</phone>
    <email>haoyu_meng@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liansheng Wang, Doctor</last_name>
      <phone>025 68303125</phone>
      <email>drlswang@njmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Haoyu Meng, Doctor</last_name>
      <phone>025 68303126</phone>
      <email>haoyu_meng@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2017</study_first_submitted>
  <study_first_submitted_qc>July 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

